GlassScriptPhysician profile
Brandy Mills
NPI 1306307350
$6,381.32
in general payments reported to CMS, 2019-2025
22 companies · $3,088 in 2025
The $3,088 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $616 · 2024: $2,678 · 2025: $3,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,222 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,222.02 |
| Education | $159.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,079.40 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $705.01 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $563.44 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $512.42 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $482.07 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $416.78 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $405.59 | 2023-2025 | Bimzelx |
| Pfizer INC. | $336.06 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $315.12 | 2023-2025 | Odomzo, Blu-U |
| Incyte Corporation | $311.70 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $284.44 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $198.62 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $165.12 | 2023-2025 | |
| Genzyme Corporation | $147.23 | 2023-2025 | |
| Lilly USA, LLC | $139.90 | 2024-2025 | Olumiant, Ebglyss, Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119.69 | 2023-2025 | Otezla, Otezla |
| Botanix Sb INC | $76.07 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $50.54 | 2024-2025 | Ycanth |
| Almirall LLC | $23.39 | 2024 | Seysara |
| Lnhc, INC | $18.43 | 2025 | Zelsuvmi |
| Organon LLC | $16.06 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.24 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.